Sunday 18 October 2026
Export BJDX’s income statement to Excel — free account
Bluejay Diagnostics, Inc.
BJDX Healthcare Medical Devices
Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00. In the quarter to June 2026, EPS grew 80.1% and free cash flow grew 20.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.75
0.03
−3.85%
Follow BJDX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 71,040.00 | 8,896.00 | 1,873.60 | 12.12 | 2.53 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 200,000.00 | 102,400.00 | 28,160.00 | 1,952.00 | 40.80 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 6 | 9 | 16 | 10 | 7 | 6 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 19.64 | — | — | — | |||||
| EBT | — | — | — | (1) | (1) | (3) | (9) | (10) | (8) | (7) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | (3,733.69) | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (1) | (1) | (3) | (9) | (10) | (8) | (7) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 415.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (8,336.49) | (11,777.92) | (13,120.00) | (14,720.00) | (14,528.00) | (456.76) | (15.25) | |||||
| Cash flow | — | — | — | (16,901.00) | (5,087.00) | (14,556.00) | (12,902.67) | (11,877.00) | (170.76) | (13.48) | |||||
| Capex | — | — | — | (60.00) | 0.00 | (79.67) | (1,998.83) | (1,006.00) | (6.70) | (0.39) | |||||
| Free cash flow | — | — | — | (16,961.00) | (5,087.00) | (14,635.67) | (14,901.50) | (12,883.00) | (177.46) | (13.87) | |||||
| Book value | — | — | — | (29,324.00) | (42,062.00) | 67,939.00 | 19,235.50 | 4,135.43 | 125.10 | 13.31 | |||||
| Shares, m | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | — | ||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| P/B | — | — | — | — | — | — | 0.65 | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | (0.24) | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (2) | (1) | (4) | (8) | (8) | (8) | (6) | ||||
| Capex | — | — | — | 0 | — | 0 | (1) | (1) | 0 | 0 | |||||
| Free cash flow | — | — | — | (2) | (1) | (4) | (9) | (9) | (8) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | (1) | 20 | 10 | 1 | 4 | 4 | ||||
| Total debt | — | — | — | 1 | 1 | — | 0 | — | — | — | |||||
| Net debt | — | — | — | 1 | (1) | (19) | (10) | (2) | (4) | (5) | |||||
| Shareholders’ equity | — | — | — | (3) | (4) | 20 | 12 | 3 | 6 | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (178.90) | (95.18) | (30.96) | (53.83) | (108.25) | (363.37) | (99.42) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (151.35) | (408.30) | (939.02) | (313.88) | (536.23) | |||||
| ROE | — | — | — | 22.97 | 32.45 | (43.13) | (58.25) | (137.90) | (485.63) | (117.02) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Jun 2022
Charts ten years each
Bluejay Diagnostics, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRIB Trinity Biotech PLC | $5.1M | — (loss-making) | — (loss-making) | +43.28% (above 0%: growing) | n/m | +75.24% (above 0%: growing) | 35.43% | (24.53%) | Compare |
| VVOS Vivos Therapeutics, Inc. | $4.8M | — (loss-making) | — (loss-making) | +34.90% (above 0%: growing) | n/m | +16.44% (above 0%: growing) | 57.31% | (93.63%) | Compare |
| INBS Intelligent Bio Solutions Inc. | $4.8M | — (loss-making) | — (loss-making) | +51.10% (above 0%: growing) | n/m | −31.59% (below 0%: shrinking) | 43.23% | (360.19%) | Compare |
| ICCM IceCure Medical Ltd. | $3.6M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| BJDX Bluejay Diagnostics, Inc. | $3.5M | 0.9× | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | |
| ADGM Adagio Medical Holdings, Inc. | $2.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.8M | 0.0× | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| NXL Nexalin Technology, Inc. | $2.6M | — (loss-making) | — (loss-making) | −82.72% (below 0%: shrinking) | n/m | −97.23% (below 0%: shrinking) | 72.95% | (18,420.49%) | Compare |
| BIOLQ Biolase, Inc. | $2.3M | — (loss-making) | — (loss-making) | −0.65% (below 0%: shrinking) | n/m | −60.22% (below 0%: shrinking) | 40.39% | (6.41%) | Compare |
| Median of peers | $3.2M | — | — | +8.04% | — | −4.49% | 37.91% | (76.46%) |
Bluejay Diagnostics, Inc. (BJDX) key facts
- Bluejay Diagnostics, Inc. (BJDX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00.
- As of October 16, 2026, BJDX traded at $0.75, a market capitalization of $3.5 million.
- Return on equity was −117.0% and debt-to-equity 0.00.
- Its Altman Z-score is −0.90 (distress zone) for fiscal 2022.
Bluejay Diagnostics, Inc. (BJDX) Latest News
No news at this impact. Lower the threshold for more.